Abstract
OBJECTIVES: To investigate the efficacy and safety of inhaled salbutamol sulfate combined with beclomethasone dipropionate in the treatment of pediatric bronchial asthma. METHODS: A total of 106 children with bronchial asthma treated from December 2022 to November 2023 were randomly assigned to a control group (n=53) and a treatment group (n=53). The control group received conventional symptomatic management plus salbutamol sulfate, while the treatment group received additional inhaled beclomethasone dipropionate. The symptom relief time, asthma control status, complete blood count parameters, interleukin-4 (IL-4) levels, interferon-γ (IFN-γ) levels, infection incidence, and adverse event rate were compared between the two groups. RESULTS: Compared with the control group, the treatment group had shorter times to symptom relief and complete symptom resolution (P<0.05). After 7 days of therapy, the treatment group showed higher asthma control score, IFN-γ level, and lymphocyte-to-monocyte ratio than the control group (P<0.05), and lower neutrophil-to-lymphocyte ratio, eosinophil-to-lymphocyte ratio, IL-4 level, infection incidence, and overall adverse event rate (P<0.05). CONCLUSIONS: Inhaled salbutamol sulfate combined with beclomethasone dipropionate improves clinical efficacy, promotes T helper 1/T helper 2 immune balance, optimizes multiple hematologic indices, and demonstrates good safety in children with bronchial asthma.